Kingdon Capital Management, L.L.C. Clovis Oncology, Inc. Transaction History

Kingdon Capital Management, L.L.C.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 14, 2019	SELL	$17.66 - $30.28 $28,256 - $48,448	-1,600 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$11.63 - $32.67 $4.54 Million - $12.8 Million	-390,359 Reduced 99.59%	1,600 $29,000
Q3 2018 Nov 14, 2018	BUY	$29.37 - $49.48 $557,178 - $938,685	18,971 Added 5.09%	391,959 $11.5 Million
Q2 2018 Aug 14, 2018	BUY	$42.06 - $62.4 $6.6 Million - $9.79 Million	156,964 Added 72.66%	372,988 $17 Million
Q1 2018 May 15, 2018	BUY	$50.12 - $67.72 $5.02 Million - $6.78 Million	100,182 Added 86.48%	216,024 $11.4 Million
Q4 2017 Feb 14, 2018	SELL	$57.69 - $84.58 $2.31 Million - $3.39 Million	-40,120 Reduced 25.72%	115,842 $7.88 Million
Q3 2017 Nov 14, 2017	BUY	$67.17 - $84.81 $10.5 Million - $13.2 Million	155,962	155,962 $12.9 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Kingdon Capital Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Kingdon Capital Management, L.L.C. with notifications on news.